Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.20)
# 2,784
Out of 5,129 analysts
75
Total ratings
43.86%
Success rate
7.64%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $22 → $20 | $22.47 | -10.99% | 17 | May 8, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $26.80 | -44.03% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $14.37 | -44.31% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $25.94 | +92.75% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $137.44 | -1.05% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $6.31 | +153.57% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $8.93 | +594.29% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.93 | +523.38% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $17.96 | +506.90% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $2.56 | +212.50% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.97 | +151.89% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $8.76 | +1,041.55% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $22.91 | -73.81% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $7.45 | +181.88% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $148.43 | -84.50% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $55.25 | -34.84% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
May 8, 2025
Maintains: Hold
Price Target: $22 → $20
Current: $22.47
Upside: -10.99%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $26.80
Upside: -44.03%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $14.37
Upside: -44.31%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $25.94
Upside: +92.75%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $137.44
Upside: -1.05%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $6.31
Upside: +153.57%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $8.93
Upside: +594.29%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.93
Upside: +523.38%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $17.96
Upside: +506.90%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $2.56
Upside: +212.50%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.97
Upside: +151.89%
Nov 11, 2022
Maintains: Buy
Price Target: $140 → $100
Current: $8.76
Upside: +1,041.55%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $22.91
Upside: -73.81%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $7.45
Upside: +181.88%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $148.43
Upside: -84.50%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $55.25
Upside: -34.84%